CO2020013588A2 - Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos - Google Patents
Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticosInfo
- Publication number
- CO2020013588A2 CO2020013588A2 CONC2020/0013588A CO2020013588A CO2020013588A2 CO 2020013588 A2 CO2020013588 A2 CO 2020013588A2 CO 2020013588 A CO2020013588 A CO 2020013588A CO 2020013588 A2 CO2020013588 A2 CO 2020013588A2
- Authority
- CO
- Colombia
- Prior art keywords
- nucleic acids
- recombinant nucleic
- acids encoding
- cosmetic proteins
- proteins
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 239000002537 cosmetic Substances 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16631—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Abstract
La presente descripción proporciona ácidos nucleicos recombinantes que comprenden uno o más polinucleótidos que codifican una o más proteínas cosméticas (por ejemplo, una o más proteínas de colágeno humanas); virus que comprenden los ácidos nucleicos recombinantes; composiciones (por ejemplo, formulaciones cosméticas) que comprenden los virus y/o ácidos nucleicos recombinantes; métodos para utilizarlos; y productos de elaboración o kits de estos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862663476P | 2018-04-27 | 2018-04-27 | |
PCT/US2019/029422 WO2019210219A1 (en) | 2018-04-27 | 2019-04-26 | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020013588A2 true CO2020013588A2 (es) | 2020-11-10 |
Family
ID=68291937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0013588A CO2020013588A2 (es) | 2018-04-27 | 2020-10-28 | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos |
Country Status (13)
Country | Link |
---|---|
US (2) | US10786438B2 (es) |
EP (1) | EP3810149A4 (es) |
JP (2) | JP2021521894A (es) |
KR (1) | KR20210005141A (es) |
CN (1) | CN112041434A (es) |
AU (2) | AU2019260757B2 (es) |
BR (1) | BR112020021804A2 (es) |
CA (1) | CA3095187A1 (es) |
CL (2) | CL2020002755A1 (es) |
CO (1) | CO2020013588A2 (es) |
MX (1) | MX2020011257A (es) |
SG (1) | SG11202009895TA (es) |
WO (1) | WO2019210219A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3712273A1 (en) | 2016-04-08 | 2020-09-23 | Krystal Biotech, LLC | Compositions for the treatment of wounds, disorders, and diseases of the skin |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
EP3752128A1 (de) * | 2018-02-16 | 2020-12-23 | Bontana Therapies Gmbh | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
US10525090B2 (en) | 2018-04-12 | 2020-01-07 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
WO2020163703A1 (en) | 2019-02-08 | 2020-08-13 | Krystal Biotech, Inc. | Compositions and methods for delivering cftr polypeptides |
US20210189427A1 (en) | 2019-12-20 | 2021-06-24 | Krystal Biotech, Inc. | Compositions and methods for gene delivery to the airways and/or lungs |
WO2021175293A1 (zh) * | 2020-03-05 | 2021-09-10 | 北京唯源立康生物科技有限公司 | 一种单纯疱疹病毒及其用途 |
CN111423516B (zh) * | 2020-04-01 | 2022-02-11 | 广州佰斯伦医疗器械有限公司 | 一种蛋白及其在创口修复及抑菌中的应用 |
CN112746076B (zh) * | 2020-12-28 | 2023-05-12 | 中吉智药(南京)生物技术有限公司 | 一种密码子优化的col7a1基因及慢病毒和应用 |
US11779660B2 (en) | 2021-04-02 | 2023-10-10 | Krystal Biotech, Inc. | Viral vectors for cancer therapy |
CN114195884B (zh) * | 2021-10-27 | 2024-03-29 | 禾美生物科技(浙江)有限公司 | 一种重组人源胶原蛋白及其制备方法 |
CN114656572B (zh) * | 2022-02-25 | 2024-07-19 | 北京大学第一医院 | 一种bp180抗体快速检测试剂盒及其制备方法 |
CN117143223B (zh) * | 2022-08-23 | 2024-03-08 | 山西锦波生物医药股份有限公司 | 一种生物合成人体结构性材料的制备方法 |
CN117230103B (zh) * | 2023-09-25 | 2024-04-19 | 爱光生物医药(南昌)有限公司 | 17型人源化胶原蛋白及其蛋白支架、填充材料及应用 |
CN117402235B (zh) * | 2023-10-25 | 2024-06-11 | 山西锦波生物医药股份有限公司 | 生物合成人体结构性材料iv型胶原蛋白的制备方法 |
CN117866077B (zh) * | 2024-03-13 | 2024-05-28 | 北京未名拾光生物技术有限公司 | 重组xvii型胶原蛋白及其表达体系 |
CN117986389B (zh) * | 2024-04-02 | 2024-06-07 | 百肽德医药生物科技(广东)有限公司 | 一种重组人源化xvii型胶原蛋白、制备方法及应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
CA2285937C (en) | 1997-04-10 | 2010-12-14 | Frederick L. Hall | Modified proteins which bind extracellular matrix components |
US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
GB9715085D0 (en) | 1997-07-18 | 1997-09-24 | Jahoda Amanda J | Gene therapy vehicle |
US6106826A (en) | 1997-12-17 | 2000-08-22 | Wisconsin Alumni Research Foundation | Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy |
GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
WO1999064094A1 (en) | 1998-06-12 | 1999-12-16 | Aradigm Corporation | Methods of delivering aerosolized polynucleotides to the respiratory tract |
WO2000040734A1 (en) | 1998-12-31 | 2000-07-13 | Arch Development Corporation | Recombinant herpes simplex virus useful for treating neoplastic disease |
CA2399371A1 (en) * | 1999-11-12 | 2001-05-17 | Fibrogen, Inc. | Animal collagens and gelatins |
GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
DE60131569T2 (de) | 2000-11-28 | 2008-10-23 | The University Of Chicago, Chicago | Genetisch veränderter herpes virus für die behandlung von herz- und gefässerkrankungen |
US8703703B2 (en) | 2006-12-20 | 2014-04-22 | University Of Central Flordia Research Foundation, Inc. | MCPIP as wound therapy |
JP2008174459A (ja) * | 2007-01-16 | 2008-07-31 | Maruzen Pharmaceut Co Ltd | 抗老化剤、並びに皮膚外用剤及び美容用飲食品 |
US20080299182A1 (en) | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
ES2590461T3 (es) | 2010-07-02 | 2016-11-22 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | La transcriptasa inversa de la telomerasa como protección frente al envejecimiento |
CN102212559B (zh) | 2011-04-14 | 2014-04-09 | 郑州威瑞生物技术有限公司 | 一种重组的hsv扩增子载体及其用途 |
US9340783B2 (en) | 2011-10-11 | 2016-05-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Exon skipping therapy for dystrophic epidermolysis bullosa |
GB201202561D0 (en) | 2012-02-15 | 2012-03-28 | Univ Dundee | Treatment of skin disorders |
EP3501550A1 (en) * | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
WO2013172721A1 (en) | 2012-05-18 | 2013-11-21 | Wise Lyn Marie | Combination treatments and compositions for wound healing |
ES2750550T3 (es) | 2013-03-01 | 2020-03-26 | Univ Minnesota | Corrección de gen a base de TALEN |
WO2015009952A1 (en) | 2013-07-17 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
WO2015117021A1 (en) * | 2014-01-31 | 2015-08-06 | Factor Bioscience Inc. | Methods and products for nucleic acid production and delivery |
JP2015221759A (ja) * | 2014-05-22 | 2015-12-10 | 株式会社東洋新薬 | コラーゲン合成促進剤、ヒアルロン酸合成促進剤及びセラミド合成促進剤 |
FR3021541B1 (fr) | 2014-05-28 | 2017-10-27 | Oreal | Procede cosmetique pour attenuer les rides |
WO2016128783A1 (en) | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions and methods for improving skin appearance |
BR112017019054B1 (pt) | 2015-03-05 | 2021-05-11 | Avon Products, Inc | método cosmético, não terapêutico, para diminuir sinais dermatológicos de envelhecimento em pele humana e produtos para cuidados com a pele |
CN109362223B (zh) | 2016-03-25 | 2023-08-25 | 普瑞菲根公司 | 高转导hsv载体 |
EP3712273A1 (en) | 2016-04-08 | 2020-09-23 | Krystal Biotech, LLC | Compositions for the treatment of wounds, disorders, and diseases of the skin |
MA45492A (fr) | 2016-06-23 | 2019-05-01 | Hopitaux Paris Assist Publique | Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène |
US10525090B2 (en) * | 2018-04-12 | 2020-01-07 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
-
2019
- 2019-04-26 SG SG11202009895TA patent/SG11202009895TA/en unknown
- 2019-04-26 KR KR1020207033734A patent/KR20210005141A/ko unknown
- 2019-04-26 US US16/395,896 patent/US10786438B2/en active Active
- 2019-04-26 JP JP2021509722A patent/JP2021521894A/ja active Pending
- 2019-04-26 CN CN201980028654.6A patent/CN112041434A/zh active Pending
- 2019-04-26 MX MX2020011257A patent/MX2020011257A/es unknown
- 2019-04-26 BR BR112020021804-9A patent/BR112020021804A2/pt unknown
- 2019-04-26 CA CA3095187A patent/CA3095187A1/en active Pending
- 2019-04-26 EP EP19792681.9A patent/EP3810149A4/en active Pending
- 2019-04-26 WO PCT/US2019/029422 patent/WO2019210219A1/en active Application Filing
- 2019-04-26 AU AU2019260757A patent/AU2019260757B2/en active Active
-
2020
- 2020-06-29 US US16/915,695 patent/US20210045988A1/en active Pending
- 2020-10-23 CL CL2020002755A patent/CL2020002755A1/es unknown
- 2020-10-28 CO CONC2020/0013588A patent/CO2020013588A2/es unknown
-
2023
- 2023-05-09 CL CL2023001338A patent/CL2023001338A1/es unknown
- 2023-12-21 AU AU2023285844A patent/AU2023285844A1/en active Pending
-
2024
- 2024-02-09 JP JP2024018447A patent/JP2024056823A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202009895TA (en) | 2020-11-27 |
AU2019260757A1 (en) | 2020-12-03 |
CL2023001338A1 (es) | 2023-10-20 |
EP3810149A1 (en) | 2021-04-28 |
EP3810149A4 (en) | 2022-08-24 |
KR20210005141A (ko) | 2021-01-13 |
CN112041434A (zh) | 2020-12-04 |
AU2019260757B2 (en) | 2023-09-28 |
CL2020002755A1 (es) | 2021-01-29 |
CA3095187A1 (en) | 2019-10-31 |
US20210045988A1 (en) | 2021-02-18 |
WO2019210219A1 (en) | 2019-10-31 |
JP2021521894A (ja) | 2021-08-30 |
MX2020011257A (es) | 2021-01-15 |
US10786438B2 (en) | 2020-09-29 |
AU2023285844A1 (en) | 2024-01-25 |
JP2024056823A (ja) | 2024-04-23 |
US20190328644A1 (en) | 2019-10-31 |
BR112020021804A2 (pt) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020013588A2 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
NI201800121A (es) | Proteínas de fusión gdf15 y usos de estas | |
CO2020009402A2 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
CL2020003176A1 (es) | Novedosas proteínas de la cápside del virus adenoasociado (divisional sol. 201900167). | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
CO2018006301A2 (es) | Mutantes de proteína f de rsv | |
PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
CL2017002514A1 (es) | Anticuerpos anti-c1s humanizados y métodos para usarlos. | |
BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
BR112022003740A2 (pt) | Anticorpos anti-cd96 e métodos de uso dos mesmos | |
BR112019008781A2 (pt) | poxvírus quiméricos sintéticos | |
CO2020000369A2 (es) | Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos | |
EA202091769A1 (ru) | Вакцины против вируса гриппа и пути их применения | |
CO2020013050A2 (es) | Enzimas quinureninasa humanas y sus usos | |
BR112018008840A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
BR112018073007A2 (pt) | terapia de combinação inicial:reforço | |
CL2020002519A1 (es) | Composiciones de erenumab y usos de las mismas |